Filing Flows › Regenxbio (RGNX) › Q3 2025
Regenxbio (RGNX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Regenxbio (RGNX) reported revenue of $29.7M for the third quarter 2025 (Q3 2025), +23% from a year earlier and +39% from the quarter before. Operating margin was -176.3%, net loss $61.9M (208.3% of revenue).
Regenxbio, Q3 2025: revenue $29.7M (+23% year over year), operating margin -176.3%, net loss $61.9M, operating cash flow −$56.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29.7M | +39% | +23% |
| Operating profit | −$52.4M | — | — |
| Net earnings | −$61.9M | — | — |
| Operating cash flow | −$56.0M | — | — |
What changed
Revenue was $29.7M in Q3 2025, up 23% year over year and up 39% from the previous quarter. License and Service was the largest line at 79% of revenue. Other Service Revenue declined 9%.
Operating costs exceeded revenue by $52.4M, an operating margin of -176.3%. Total costs fell 5% while revenue rose 23%. The quarter ended with a net loss of $61.9M, narrower than the previous quarter's $70.9M loss.
Operating cash flow was −$56.0M. Non-cash charges added back $3.9M of depreciation and amortization and $9.0M of share-based compensation. Working capital and other items used $6.9M. Capital expenditures of $491K exceeded it, leaving free cash flow of −$56.5M.
Questions
What was Regenxbio's revenue in the third quarter 2025?
Regenxbio (RGNX) reported revenue of $29.7M for the third quarter 2025 (Q3 2025), +23% from a year earlier and +39% from the quarter before.
Was Regenxbio profitable in the third quarter 2025?
Operating loss was $52.4M (-176.3% of revenue) and net loss $61.9M.
Source: Regenxbio 10-Q on SEC EDGAR.